Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — | $0 | $0 | $11.13M | $2.26M |
| Gross profit | $0 | $0 | $0 | — | $0 | $0 | $11.13M | $2.26M |
| Gross margin | — | — | — | — | — | — | 100.0% | 100.0% |
| Research and development | $28.87M | $27.38M | $23.13M | $20.36M | $22.05M | $18.92M | $14.55M | $11.81M |
| Selling, general and administrative | $14.08M | $9.40M | $6.02M | $5.92M | $5.67M | $6.07M | $4.27M | $3.46M |
| Operating expenses | $42.95M | $36.77M | $29.16M | $26.28M | $27.72M | $24.98M | $18.83M | $15.27M |
| Operating income | −$42.95M | −$36.77M | −$29.16M | −$26.28M | −$27.72M | −$24.98M | −$7.70M | −$13.01M |
| Operating margin | — | — | — | — | — | — | -69.1% | -575.2% |
| EBITDA | −$42.38M | −$36.24M | −$28.65M | −$25.79M | −$27.23M | −$24.58M | −$7.32M | −$12.65M |
| Interest income | $2.21M | $2.90M | $2.02M | $1.71M | $1.79M | $729.54K | $686.57K | $453.15K |
| Interest expense | $0 | $0 | −$3.05M | — | $0 | $0 | $0 | — |
| Income before taxes | −$40.73M | −$33.94M | −$30.17M | −$24.57M | −$25.91M | −$24.39M | −$7.12M | −$12.56M |
| Income taxes | $1.60K | $0 | $1.60K | — | $1.60K | $0 | $1.60K | — |
| Net income | −$40.73M | −$33.94M | −$30.17M | −$24.57M | −$25.91M | −$24.39M | −$7.12M | −$12.56M |
| Net margin | — | — | — | — | — | — | -63.9% | -555.2% |
| EPS, basic | −$0.70 | −$0.59 | −$0.62 | −$0.54 | −$0.57 | −$0.53 | −$0.16 | −$0.38 |
| EPS, diluted | −$0.70 | −$0.59 | −$0.62 | −$0.54 | −$0.57 | −$0.53 | −$0.16 | −$0.38 |
| Diluted shares | 57.93M | 57.43M | 48.85M | 45.72M | 45.71M | 45.64M | 44.59M | 33.09M |
Figures describe Capricor Therapeutics shares, not any token. As of Aug 14, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.